Albany, NY -- (SBWIRE) -- 06/18/2020 -- Familial Hypercholesterolemia Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Familial Hypercholesterolemia Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. The total diagnosed prevalent population of Familial Hypercholesterolemia in the 7MM was 965,405 in 2017.
2. The diagnosed prevalent population of Familial Hypercholesterolemia in the United States was 244,214 in 2017.
3. The diagnosed prevalent population of Familial Hypercholesterolemia in Japan in 2017 was 221,519
4. Familial Hypercholesterolemia affects both females and males equally.
Key benefits of the report
1. Familial Hypercholesterolemia market report covers a descriptive overview and comprehensive insight of the Familial Hypercholesterolemia epidemiology and Familial Hypercholesterolemia market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Familial Hypercholesterolemia market report provides insights into the current and emerging therapies.
3. Familial Hypercholesterolemia market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Familial Hypercholesterolemia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Familial Hypercholesterolemia market.

Request for sample pages

"The market size of Familial Hypercholesterolemia in the 7MM in 2017- 1,069.27 USD Million."

Early diagnosis and Familial Hypercholesterolemia treatment are vital to reduce the risk of premature atherosclerotic cardiovascular disease and death. The goal of Familial Hypercholesterolemia treatment is to reduce LDL-C by 50 % from baseline levels with lifestyle modification, pharmacologic lipid-lowering therapy, and LDL apheresis and in rare cases, liver transplantation.

Statins are first-line pharmacologic therapy agents in the treatment of Familial Hypercholesterolemia as they reduce cardiovascular mortality even in receptor-negative patients. The FDA has approved many statins for the treatment of Familial Hypercholesterolemia, namely, Mevacor (lovastatin), Pravachol (pravastatin), and Zocor (simvastatin) which are fungal-derived statins, while Lipitor (atorvastatin), Lescol (fluvastatin), Livalo (pitavastatin), and Ezallortm (rosuvastatin) are synthetic compounds.

Mipomersen is a second-generation antisense oligonucleotide that targets the messenger ribonucleic acid (mRNA) that encodes ApoB-100 produced by the liver. It is marketed by the brand name Kynamro. It distributes mainly to the liver, where it forms a duplex with the target mRNA, causing the mRNA to be cleaved by RNase H and therefore unable to be translated to apoB-100. Hepatic Apo mRNA silencing gives rise to reductions in hepatic Apo and plasma total cholesterol, LDL-cholesterol, and Apo concentrations in a dose- and time-dependent manner.

The launch of the emerging therapies is expected to significantly impact Familial Hypercholesterolemia treatment scenario in the upcoming years:-
Drugs covered
1. Evinacumab (REGN1500)
2. Inclisiran (ALN-PCSSC)
3. LIB003 + Evolocumab
4. Gemcabene
5. Resmetirom (MGL-3196)
6. ARO-ANG3
And many others

The key players in Familial Hypercholesterolemia market are:
1. Regeneron Pharmaceuticals
2. Novartis
3. LIB Therapeutics
4. NeuroBo Pharmaceuticals
5. Madrigal Pharmaceuticals
6. Arrowhead Pharmaceuticals
And many others

Table of contents
1 Key Insights
2 Familial Hypercholesterolemia Market Overview at a Glance
3 Familial Hypercholesterolemia Disease Background and Overview
4 Diagnostic guidelines for Familial Hypercholesterolemia by the American Heart Association (AHA)
5 Diagnostic guidelines for Familial Hypercholesterolemia by the National Institute for Health and Care Excellence (NICE)
6 Recognized Establishments
7 Familial Hypercholesterolemia Epidemiology and Patient Population: Key Findings
8 Country Wise-Epidemiology of Familial Hypercholesterolemia
8.1 United States
8.2 EU5 Countries
8.3 Germany
8.4 France
8.5 Italy
8.6 Spain
8.7 United Kingdom
8.8 Japan
9 Familial Hypercholesterolemia Treatment
10 Familial Hypercholesterolemia Treatment guidelines by the American Heart Association (AHA)
11 Familial Hypercholesterolemia Treatment guidelines by the National Institute for Health and Care Excellence (NICE)
12 Treatment guidelines for Familial Hypercholestrolemia by the Japan Atherosclerosis Society and the Asian Pacific Society of Atherosclerosis and Vascular Diseases
13 Unmet Needs
15 Familial Hypercholesterolemia Marketed Drugs
15.1 Marketed Drugs Key-cross Competition
15.2 Praluent (alirocumab): Sanofi/ Regeneron Pharmaceuticals
15.3 Repatha (evolocumab): Amgen
15.4 Nustendi (bempedoic acid / ezetimibe): Esperion Therapeutics
16 Familial Hypercholesterolemia Emerging Drugs
16.1 Key Cross Competition
16.2 Evinacumab (REGN1500): Regeneron Pharmaceuticals
16.3 Inclisiran (ALN-PCSSC): Novartis
16.4 LIB003 + Evolocumab: LIB Therapeutics
16.5 Gemcabene: NeuroBo Pharmaceuticals
16.6 Resmetirom (MGL-3196): Madrigal Pharmaceuticals
16.7 ARO-ANG3: Arrowhead Pharmaceuticals
17 Familial Hypercholesterolemia 7 Major Market Analysis
17.4 United States Market Size
17.5 Germany Market Size
17.6 France Market Size
17.7 Italy Market Size
17.8 Spain Market Size
17.9 United Kingdom Market Size
17.10 Japan market Size
18 Case Reports
19 Market Drivers
20 Market Barriers
21 SWOT Analysis for Familial Hypercholesterolemia
22 Appendix
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight